

Reference list

1. Rodrigues CMC, Plotkin SA. Impact of Vaccines; Health, Economic and Social Perspectives. *Front Microbiol.* 2020 Jul 14;11:1526.
2. Ehreth J. The global value of vaccination. *Vaccine.* 2003 Jan 30;21(7):596–600.
3. World Health Organization. State of the world's vaccines and immunization. *Vaccins et vaccination : la situation dans le monde* [Internet]. 3rd edition. 2009 [cited 2024 Apr 4]; Available from: <https://iris.who.int/handle/10665/44169>
4. 2018 assessment report of the Global Vaccine Action Plan [Internet]. [cited 2024 Apr 4]. Available from: <https://www.who.int/publications-detail-redirect/2018-assessment-report-of-the-global-vaccine-action-plan>
5. Lindstrand A, Cherian T, Chang-Blanc D, Feikin D, O'Brien KL. The World of Immunization: Achievements, Challenges, and Strategic Vision for the Next Decade. *J Infect Dis.* 2021 Sep 30;224(Suppl 4):S452–67.
6. Wiseman V, Mitton C, Doyle-Waters MM, Drake T, Conteh L, Newall AT, et al. Using Economic Evidence to Set Healthcare Priorities in Low-Income and Lower-Middle-Income Countries: A Systematic Review of Methodological Frameworks. *Health Econ.* 2016 Feb;25(Suppl Suppl 1):140–61.
7. Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny MP, et al. Cost–effectiveness thresholds: pros and cons. *Bull World Health Organ.* 2016 Dec 1;94(12):925–30.
8. Thomas R, Chalkidou K. Cost–effectiveness analysis. In: *Health system efficiency: How to make measurement matter for policy and management* [Internet] [Internet]. European Observatory on Health Systems and Policies; 2016 [cited 2024 Apr 4]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK436886/>
9. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. *Methods for the Economic Evaluation of Health Care Programmes* [Internet]. Oxford, UNITED KINGDOM: Oxford University Press; 2015 [cited 2023 Sep 3]. Available from: <http://ebookcentral.proquest.com/lib/unimelb/detail.action?docID=4605509>
10. Newall AT, Jit M, Hutubessy R. Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines. *PharmacoEconomics.* 2014 Jun 1;32(6):525–31.
11. Claxton K, Briggs A, Buxton MJ, Culyer AJ, McCabe C, Walker S, et al. Value based pricing for NHS drugs: an opportunity not to be missed? *BMJ.* 2008 Feb 2;336(7638):251–4.
12. Chi YL, Blecher M, Chalkidou K, Culyer A, Claxton K, Edoaka I, et al. What next after GDP-based cost-effectiveness thresholds? [Internet]. *Gates Open Research*; 2020 [cited 2024 Apr 4]. Available from: <https://gatesopenresearch.org/articles/4-176>

13. Woods B, Revill P, Sculpher M, Claxton K. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. *Value Health*. 2016 Dec;19(8):929–35.
14. Robinson LA, Hammitt JK, Chang AY, Resch S. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. *Health Policy and Planning*. 2017 Feb 1;32(1):141–5.
15. Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Muehlberger N, et al. Systematic overview of cost–effectiveness thresholds in ten countries across four continents. *Journal of Comparative Effectiveness Research*. 2015 Sep;4(5):485–504.
16. Kazibwe J, Gheorghe A, Wilson D, Ruiz F, Chalkidou K, Chi YL. The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review. *Value Health*. 2022 Mar;25(3):385–9.
17. Ray S, Pathak S, Kshtriya P. Critical Analysis of Economic Evaluation of the Childhood Rotavirus Vaccination in Low- and Lower-Middle-Income Countries: A Systematic Review. *Value in Health Regional Issues*. 2023 Nov 1;38:18–28.
18. Tu HAT, Woerdenbag HJ, Kane S, Rozenbaum MH, Li SC, Postma MJ. Economic evaluations of rotavirus immunization for developing countries: a review of the literature. *Expert Review of Vaccines*. 2011 Jul 1;10(7):1037–51.
19. Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost–effectiveness of interventions: alternative approaches. *Bull World Health Organ*. 2015 Feb 1;93(2):118–24.
20. Meyer-Rath G, Rensburg C van, Larson B, Jamieson L, Rosen S. Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case. *PLOS ONE*. 2017 Oct 26;12(10):e0186496.
21. Revill P, Ochalek J, Lomas J, Nakamura R, Woods B, Rollinger A, et al. Cost-Effectiveness Thresholds: Guiding Health Care Spending for Population Health Improvement. In: *World Scientific Series in Global Health Economics and Public Policy* [Internet]. WORLD SCIENTIFIC; 2020 [cited 2024 Apr 4]. p. 75–97. Available from: https://www.worldscientific.com/doi/abs/10.1142/9789813272378_0003
22. Thokala P, Ochalek JM, Leech A. Cost effectiveness thresholds: the past, the present and the future. [cited 2024 May 4]; Available from: <https://core.ac.uk/display/151177610?source=2>
23. Edoka IP, Stacey NK. Estimating a cost-effectiveness threshold for health care decision-making in South Africa. *Health Policy and Planning*. 2020 Jun 1;35(5):546–55.
24. Thokala, Praveen and Ochalek, Jessica Marie object. Cost effectiveness thresholds: the past, the present and the future. [cited 2024 May 4]; Available from: <https://core.ac.uk/reader/151177610>
25. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. *BMJ Global Health*. 2018 Nov 1;3(6):e000964.

The Use of Cost-effectiveness Thresholds for Evaluating Vaccinations in LMICs and the Implications of Health-Opportunity Based Thresholds: A Literature Review and Quantitative Analysis

Lynn Daryl Feliciano-Villamater

26. Pichon-Riviere A, Drummond M, Palacios A, Garcia-Marti S, Augustovski F. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. *The Lancet Global Health*. 2023 Jun;11(6):e833–42.
27. Santos AS, Guerra-Junior AA, Godman B, Brandão CMR. COST-EFFECTIVENESS THRESHOLDS: METHODS FOR DEFINITION AND CASES AROUND THE WORLD.
28. Leech AA, Kim DD, Cohen JT, Neumann PJ. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. *Value in Health*. 2018 Jul 1;21(7):759–61.
29. Fesenfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review. *Vaccine*. 2013 Aug 20;31(37):3786–804.
30. Services EA. Literature Review in Research Writing | Elsevier Blog [Internet]. Elsevier Author Services - Articles. 2020 [cited 2024 Jun 18]. Available from: <https://scientific-publishing.webshop.elsevier.com/research-process/importance-literature-review-research-writing/>
31. Booth D. LibGuides: Research Methods: What are research methods? [Internet]. [cited 2024 Jun 16]. Available from: <https://libguides.newcastle.edu.au/researchmethods/home>
32. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021 Mar 29;n71.
33. Databases - Center for the Evaluation of Value and Risk in Health [Internet]. [cited 2024 Apr 26]. Available from: <https://cevr.tuftsmedicalcenter.org/databases>
34. Neumann PJ, Thorat T, Zhong Y, Anderson J, Farquhar M, Salem M, et al. A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. *PLoS One*. 2016 Dec 22;11(12):e0168512.
35. World Bank Blogs [Internet]. [cited 2024 Apr 9]. New World Bank country classifications by income level: 2020-2021. Available from: <https://blogs.worldbank.org/en/opendata/new-world-bank-country-classifications-income-level-2020-2021>
36. World Bank Open Data [Internet]. [cited 2024 Apr 27]. World Bank Open Data. Available from: <https://data.worldbank.org>
37. McHugh ML. The Chi-square test of independence. *Biochem Med (Zagreb)*. 2013 Jun 15;23(2):143–9.
38. Yeager K. LibGuides: SPSS Tutorials: Chi-Square Test of Independence [Internet]. [cited 2024 May 29]. Available from: <https://libguides.library.kent.edu/SPSS/ChiSquare>
39. Logistic Regression in Medical Research - PMC [Internet]. [cited 2024 May 29]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785709/>

40. Mauskopf J, Standaert B, Connolly MP, Culyer AJ, Garrison LP, Hutubessy R, et al. Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report. *Value in Health*. 2018 Oct 1;21(10):1133–49.
41. Gosset A, Diallo MY, Betsem E, Schaeffer L, Meda N, Vray M, et al. Cost-effectiveness of adding a birth dose of hepatitis B vaccine in the Dafra district of the Hauts-Bassins Region in Burkina Faso (NéoVac Study). *Vaccine*. 2021 Jul 30;39(33):4659–70.
42. Krishnamoorthy Y, Elias SK, Nair NP, Sakthivel M, Sarveswaran G, Chinnakali P. Impact and cost effectiveness of pneumococcal conjugate vaccine in India. *Vaccine*. 2019 Jan 21;37(4):623–30.
43. Shoukat A, Vilches T, Moghadas SM. Cost-effectiveness of a potential Zika vaccine candidate: a case study for Colombia. *BMC Med*. 2018 Jul 3;16:100.
44. Knerer G, Currie CSM, Brailsford SC. The economic impact and cost-effectiveness of combined vector-control and dengue vaccination strategies in Thailand: results from a dynamic transmission model. *PLoS Negl Trop Dis*. 2020 Oct;14(10):e0008805.
45. Russell LB, Kim SY, Cosgriff B, Pentakota SR, Schrag SJ, Sobanjo-ter Meulen A, et al. Cost-effectiveness of maternal GBS immunization in low-income sub-Saharan Africa. *Vaccine*. 2017 Dec 14;35(49Part B):6905–14.
46. Sarker AR, Sultana M, Mahumud RA, Van Der Meer R, Morton A. Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh. *Hum Vaccin Immunother*. 2017 Dec 12;14(1):189–98.
47. Kebede TT, Svensson M, Addissie A, Trollfors B, Andersson R. Cost-effectiveness of childhood pneumococcal vaccination program in Ethiopia: results from a quasi-experimental evaluation. *BMC Public Health*. 2019 Aug 9;19(1):1078.
48. Anwari P, Debellut F, Vodicka E, Clark A, Farewar F, Zhwak ZA, et al. Potential health impact and cost-effectiveness of bivalent human papillomavirus (HPV) vaccination in Afghanistan. *Vaccine*. 2020 Feb 5;38(6):1352–62.
49. Ahmed N, Giorgakoudi K, Usuf E, Okomo U, Clarke E, Kampmann B, et al. Potential cost-effectiveness of a maternal Group B streptococcal vaccine in The Gambia. *Vaccine*. 2020 Mar 30;38(15):3096–104.
50. Edney LC, Lomas J, Karnon J, Vallejo-Torres L, Stadhouders N, Siverskog J, et al. Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates. *PharmacoEconomics*. 2022 Jan 1;40(1):31–43.
51. Isaranuwatthai W, Teerawattananon Y, Archer RA, Luz A, Sharma M, Rattanavipapong W, et al. Prevention of non-communicable disease: best buys, wasted buys, and contestable buys. *BMJ*. 2020 Jan 28;368:m141.
52. Nimdet K, Ngorsuraches S. Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand. *BMJ Open*. 2015 Oct 1;5(10):e008123.